Development of Monocarboxylate Transporter 4 Inhibitor/Docetaxel-Loaded Multilayer Nanoparticles for Prostate Cancer Combination Therapy.
- 13 November 2026
- journal article
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- p. 1-37
Abstract
No abstract availableFunding Information
- National Institute on Minority Health and Health Disparities (5U54MD007582)
This publication has 58 references indexed in Scilit:
- Nilotinib Tartrate Encapsulated Polycaprolactone Polymeric Nanoparticle Fabricated With Lactoferrin for the Treatment of Colorectal Cancer: In-Silico and In-Vitro InvestigationBioNanoScience, 2026
- Phosphinate or Urea? Synthesis and Biological Evaluation of Prostate Specific Membrane Antigen‐Targeted Fluorophores With Different Zinc‐Binding MotifChemMedChem, 2026
- Innovative plasma spray coating of HA-Ti-MgO composite on Ti6Al4V alloy for enhanced performanceJournal of Materials Science: Materials in Medicine, 2025
- Dip Coating: Simple Way of Coating Thin Films2023
- Preclinical Models of Neuroendocrine Prostate CancerCurrent Protocols, 2023
- Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohortBJUI Compass, 2021
- Emerging Variants of Castration-Resistant Prostate CancerCurrent Oncology Reports, 2017
- Sodium Acetate Coated Tenofovir-Loaded Chitosan Nanoparticles for Improved Physico-Chemical PropertiesPharmaceutical Research, 2015
- Prolonged Hypoxia Induces Monocarboxylate Transporter-4 Expression in Mesenchymal Stem Cells Resulting in a Secretome that is Deleterious to Cardiovascular RepairStem Cells, 2015
- Optimizing phenylethylphosphonamidates for the inhibition of prostate-specific membrane antigenBioorganic & Medicinal Chemistry, 2006